Leo Pharma Purchases Astellas’ Dermatology Business

Skin solutions drugmaker Leo Pharma has reached an agreement to acquire Astellas Pharma’s global dermatology business for $727 million.

Under the agreement, Denmark-based Leo will acquire Astellas’ Protopic for the treatment of atopic dermatitis, as well as other products for acne and skin infection, including Zineryt, Locoid and Locobase.

The transaction is expected to close in the first quarter of 2016.